| abstract |
(57) [Summary]nThe present invention relates to a novel heteroaryldiazabicyclo represented by general formula (I) in labeled or unlabeled form, which has been found to be a cholinergic ligand at the nicotinic acetylcholine receptor. It relates to an alkane derivative, any enantiomer thereof, any mixture thereof, the N-oxide or a pharmaceutically acceptable salt thereof. Due to their pharmacological characteristics, the compounds of the present invention may be used in various diseases or disorders related to the cholinergic system of the central nervous system (CNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders. It is effective in the treatment of diseases or disorders related to neurodegeneration, diseases or disorders related to inflammation, pain, withdrawal symptoms caused by discontinuation of chemical abuse. |